Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Dyadic International, Inc.
Dyadic International, Inc. and Proliant Health and Biologicals announce Recombinant Albumin Development and Commercialization Partnership
June 28, 2024
From
Dyadic International, Inc.
Via
GlobeNewswire
Tickers
DYAI
Dyadic to Attend Industry Events in June
May 30, 2024
From
Dyadic International, Inc.
Via
GlobeNewswire
Tickers
DYAI
Dyadic to Attend Industry and Investor Events in May
May 08, 2024
From
Dyadic International, Inc.
Via
GlobeNewswire
Tickers
DYAI
Dyadic to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024
April 30, 2024
From
Dyadic International, Inc.
Via
GlobeNewswire
Tickers
DYAI
Dyadic Announces Change in Board and Management Leadership Roles
March 28, 2024
From
Dyadic International, Inc.
Via
GlobeNewswire
Tickers
DYAI
Dyadic to Attend Industry Events in April
March 27, 2024
From
Dyadic International, Inc.
Via
GlobeNewswire
Tickers
DYAI
Dyadic Announces Publication of C1 Monoclonal Antibody in Nonhuman Primate Study in Nature Communications
March 26, 2024
From
Dyadic International, Inc.
Via
GlobeNewswire
Tickers
DYAI
Dyadic to Attend Future Food Tech Event March 21 – 22, 2024 in San Francisco, California
March 21, 2024
From
Dyadic International, Inc.
Via
GlobeNewswire
Tickers
DYAI
Dyadic to Report Full Year 2023 Financial Results and Host Conference call on Thursday, March 28, 2024
March 14, 2024
From
Dyadic International, Inc.
Via
GlobeNewswire
Tickers
DYAI
CORRECTION – Dyadic Announces Closing of Private Placement of $6.0 Million Convertible Notes to Accelerate Near-Term Revenue Growth and Commercialization
March 11, 2024
From
Dyadic International, Inc.
Via
GlobeNewswire
Tickers
DYAI
Dyadic Announces Closing of Private Placement of $6.0 Million Convertible Notes to Accelerate Near-Term Revenue Growth and Commercialization
March 11, 2024
From
Dyadic International, Inc.
Via
GlobeNewswire
Tickers
DYAI
Dyadic to Attend Industry Events in March
March 01, 2024
From
Dyadic International, Inc.
Via
GlobeNewswire
Tickers
DYAI
Dyadic Announces Strategic Partnership Agreement to Develop Affordable Rabies Prophylactics and Vaccines Using its Proprietary C1 Cell Microbial Protein Production Platform
February 28, 2024
From
Dyadic International, Inc.
Via
GlobeNewswire
Tickers
DYAI
Dyadic Advances Collaboration with Israel Institute for Biological Research (IIBR) Targeting Bio-Threats and Emerging Disease Solutions
February 21, 2024
From
Dyadic International, Inc.
Via
GlobeNewswire
Tickers
DYAI
Dyadic and Cygnus Technologies Announce Partnership To Provide C1 HCP ELISA Assay to Enhance Quality Assurance in Biomanufacturing
February 13, 2024
From
Dyadic International, Inc.
Via
GlobeNewswire
Tickers
DYAI
MRVI
Dyadic Announces Research and Development Collaboration Agreement with Global Biopharmaceutical Company
February 06, 2024
From
Dyadic International, Inc.
Via
GlobeNewswire
Tickers
DYAI
Dyadic to Attend BIO CEO & Investor Conference and European Industry Events
February 01, 2024
From
Dyadic International, Inc.
Via
GlobeNewswire
Tickers
DYAI
Dyadic to Attend J.P. Morgan 42nd Annual Healthcare Conference
January 02, 2024
From
Dyadic International, Inc.
Via
GlobeNewswire
Tickers
DYAI
Dyadic Attends Investor Events in December
November 30, 2023
From
Dyadic International, Inc.
Via
GlobeNewswire
Tickers
DYAI
Dyadic Announces Top-Line Results from its Successful Phase 1 Clinical Trial for a First-in-Human Filamentous Fungal-Based Vaccine Candidate
November 29, 2023
From
Dyadic International, Inc.
Via
GlobeNewswire
Tickers
DYAI
Dyadic’s C1 Platform to be Used to Produce Vaccines for Humans and Animals in Africa
November 20, 2023
From
Dyadic International, Inc.
Via
GlobeNewswire
Tickers
DYAI
Dyadic to Present at Industry Events in November
October 30, 2023
From
Dyadic International, Inc.
Via
GlobeNewswire
Tickers
DYAI
Dyadic to Report Third Quarter 2023 Financial Results on Wednesday, November 8, 2023
October 25, 2023
From
Dyadic International, Inc.
Via
GlobeNewswire
Tickers
DYAI
Dyadic Appoints Doug Pace to Its Executive Leadership Team
October 09, 2023
From
Dyadic International, Inc.
Via
GlobeNewswire
Tickers
DYAI
Dyadic’s C1 Platform Selected by the Vaccine and Immunotherapy Center (“VIC”) at Massachusetts General Hospital as Part of VIC’s $5.88 Million Award by U.S. DoD to Develop a Self-Assembling Vaccine (SAV) Platform for Rapid Production of Prophylactic
October 05, 2023
From
Dyadic International, Inc.
Via
GlobeNewswire
Tickers
DYAI
Dyadic to Present at Industry and Investor Events in October
September 29, 2023
From
Dyadic International, Inc.
Via
GlobeNewswire
Tickers
DYAI
Dyadic and bYoRNA Announce a Collaboration Targeting the Production of Abundant, Low-Cost mRNA From C1-Cells
September 26, 2023
From
Dyadic International, Inc.
Via
GlobeNewswire
Tickers
DYAI
Dyadic Announces Development and License Agreement to Commercialize Animal-Free Alternative Proteins Using Dapibus™
September 19, 2023
From
Dyadic International, Inc.
Via
GlobeNewswire
Tickers
DYAI
Dyadic to Present at BioProcess International
September 12, 2023
From
Dyadic International, Inc.
Via
GlobeNewswire
Tickers
DYAI
Dyadic Announces Continued Progress Towards Commercialization of Animal-Free Recombinant Serum Albumin
August 07, 2023
From
Dyadic International, Inc.
Via
GlobeNewswire
Tickers
DYAI
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.